6.38
Precedente Chiudi:
$6.44
Aprire:
$6.42
Volume 24 ore:
1.42M
Relative Volume:
1.90
Capitalizzazione di mercato:
$241.84M
Reddito:
$147.12M
Utile/perdita netta:
$-33.88M
Rapporto P/E:
-13.28
EPS:
-0.4805
Flusso di cassa netto:
$2.63M
1 W Prestazione:
-1.09%
1M Prestazione:
+53.37%
6M Prestazione:
+22.69%
1 anno Prestazione:
-2.30%
Lifecore Biomedical Inc Stock (LFCR) Company Profile
Nome
Lifecore Biomedical Inc
Settore
Telefono
(952) 368-4300
Indirizzo
3515 LYMAN BOULEVARD, CHASKA
Compare LFCR vs TAK, TEVA, HLN, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
LFCR
Lifecore Biomedical Inc
|
6.38 | 241.84M | 147.12M | -33.88M | 2.63M | -0.4805 |
|
TAK
Takeda Pharmaceutical Co Adr
|
19.67 | 62.84B | 29.91B | 1.30B | 3.49B | 0.4056 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.50 | 48.40B | 17.53B | 1.58B | 444.18M | 1.3457 |
|
HLN
Haleon Plc Adr
|
10.13 | 44.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
ZTS
Zoetis Inc
|
79.38 | 32.80B | 9.51B | 2.64B | 2.14B | 6.0361 |
|
UTHR
United Therapeutics Corp
|
533.12 | 22.87B | 3.17B | 1.29B | 1.01B | 27.09 |
Lifecore Biomedical Inc Stock (LFCR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-17 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2025-09-04 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2025-05-21 | Iniziato | William Blair | Outperform |
| 2024-09-05 | Iniziato | Craig Hallum | Buy |
| 2024-08-28 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| 2023-03-20 | Downgrade | Stephens | Overweight → Equal-Weight |
Mostra tutto
Lifecore Biomedical Inc Borsa (LFCR) Ultime notizie
Press Releases about Mistras Group Inc Common Stock (NYSE:MG) - FinancialContent
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RXO Inc. (NYSE – RXO), PTC Inc. (Nasdaq – PTC), Lifecore Biomedical, Inc. (Nasdaq – LFCR), WaFd, Inc. (Na - StreetInsider
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RXO Inc. (NYSE – RXO), PTC Inc. (Nasdaq – PTC), Lifecore Biomedical, Inc. (Nasdaq – LFCR), WaFd, Inc. (Nasdaq – WAFD) - Procurement Magazine
Halper Sadeh LLC is Investigating Whether MG, LFCR, MGLD are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Capital Bancorp, Inc. (Nasdaq – CBNK), Lifecore Biomedical, Inc. (Nasdaq – LFCR), MISTRAS Group, Inc. (NYSE – MG), Utz Brands, Inc. (NYSE – UTZ) - Supply Chain Digital
Votes against certain rival proposals are part of Wynnefield's merger pledge at Lifecore Biomedical (LFCR). - Stock Titan
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Lifecore Biomedical, Inc. (NASDAQ: LFCR) - Morningstar
Lifecore Biomedical (Nasdaq: LFCR) Closes up on Acquisition News - Investorideas.com
Form 13D/A LIFECORE BIOMEDICAL For: 28 September By Investing.com - Investing.com Nigeria
Form 13D/A LIFECORE BIOMEDICAL For: 28 September By Investing.com - Investing.com India
Form 13D/A LIFECORE BIOMEDICAL For: 28 September By Investing.com - Investing.com Canada
A $6.28-a-share merger gets a voting pledge from Legion Partners at Lifecore Biomedical (LFCR). - Stock Titan
LFCR Stock Alert: Halper Sadeh LLC is Investigating Whether Lifecore Biomedical, Inc. is Obtaining a Fair Price for its Shareholders - Business Wire
Form 8K Lifecore Biomedical Inc For: 28 September By Investing.com - Investing.com Nigeria
Form 8K Lifecore Biomedical Inc For: 28 September By Investing.com - Investing.com UK
Lifecore Biomedical to be acquired by Webster Equity Partners - TradingView
A 49.5% premium is built into Lifecore Biomedical’s (LFCR) proposed sale. The cash price is only part of the deal. - Stock Titan
Lifecore Biomedical to be Acquired by Webster Equity Partners - GlobeNewswire
Lifecore Biomedical: A Messy Balance Sheet, A Much Better Business (NASDAQ:LFCR) - Seeking Alpha
Lifecore plans customer meetings in Milan this October - Stock Titan
Lifecore Biomedical to Participate at CPHI Global Conference - Yahoo Finance
Lifecore Strikes Tech Transfer Deal for Commercial Manufacturing of Major Pharma Company Injectable - Contract Pharma
Lifecore Biomedical Signs New Commercial Transfer Agreement for Marketed Injectable Product - Quiver Quantitative
A marketed injectable drug is expected to bring Lifecore revenue in 2028. - Stock Titan
LFCR Q2 2026 Earnings: Narrower Loss of -$0.19 Beats Estimates, Shares Dip 1.35%Revenue Guidance Update - vinanet.vn
Lifecore (LFCR) Results at a Glance: EPS Lands Above Forecast in Latest Trading; Session Move: Shares Rise 0.22% at the CloseEarnings Season Preview - vinanet.vn
Lifecore (LFCR) Earnings Reading: EPS Prints Above Forecast at the Close; After Results: Shares Move 2.42% Down on the DayGuidance Downgrade Alert - vinanet.vn
LFCR | Lifecore Biomedical, Inc. Common FinancialsRevenue Breakdown - Quiver Quantitative
Lifecore Biomedical Earnings Call Balances Growth and Strain - TipRanks
Lifecore (LFCR) Quarterly Scorecard: EPS Beats Its Estimate; The Stock Records a 1.83% Increase on the DayROA Comparison - vinanet.vn
Core Thesis Behind Lifecore Biomedical (LFCR): Monetizing Excess Capacity - Yahoo Finance
Avoiding Lag: Real-Time Signals in (LFCR) Movement - Stock Traders Daily
Lifecore Biomedical (LFCR) Q2 2026 Earnings Call Transcript - AOL.com
LFCR Q2 2026 Earnings: Narrower-Than-Expected Loss Delivers 16.59% EPS SurpriseAnalyst Coverage Count - vinanet.vn
Lifecore Biomedical (LFCR) Holds Above $4.50 Support as Shares Edge LowerSell Signal Alerts - vinanet.vn
LFCR Q2 2026 Earnings: Narrower-than-Expected Loss Offers Modest EncouragementGuidance vs Actual - vinanet.vn
Lifecore Biomedical (LFCR) Holds Above $4.50 Support as Shares Edge LowerCash Secured Put - dars.gov.et
Judge approves $3.75 million Lifecore investor settlement - Minnesota Lawyer
Lifecore Biomedical (LFCR) Q2 2026 Earnings Call Transcript - The Globe and Mail
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore - TMX Newsfile
Lifecore Biomedical Reports Financial Results for the Second Quarter Ended June 30, 2026, and Provides Corporate Update - marketscreener.com
Lifecore Biomedical, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Discipline and Rules-Based Execution in LFCR Response - Stock Traders Daily
Earnings call transcript: Lifecore Biomedical tops revenue view in Q2 2026 - Investing.com Canada
Lifecore Biomedical (NASDAQ:LFCR) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
Earnings call transcript: Lifecore Biomedical tops revenue view in Q2 2026 - Investing.com
Transcript : Lifecore Biomedical, Inc., Q2 2026 Earnings Call, Aug 05, 2026 - marketscreener.com
Lifecore Biomedical, Inc. Reaffirms Earnings Guidance for the Calendar Year 2026 - marketscreener.com
LFCR: Revenue and profit declined, but cost cuts and new wins support strong long-term growth outlook - TradingView
Lifecore Biomedical, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Lifecore Biomedical Inc Azioni (LFCR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):